Skip to main content

Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage

Even if the FDA grants full approval of the Alzheimer's treatment Leqembi, the rollout of the treatment will take years.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.